Big pharma Merck (NYSE:MRK) said Tuesday that it will stop a phase-three trial of cancer drug Keytruda for melanoma because the trial had already met its goals ahead of schedule. Merck's stock rose about 1% in early trading.
The trial, called Keynote-006, compared Keytruda head to head with Bristol-Myers Squibb's (NYSE:BMY) Yervoy, currently the standard of care for melanoma, in previously untreated patients. Merck said that the trial had met its endpoints in progression-free survival and overall survival — the most imp...
Also read: Apple’s stock is the biggest drag on the Dow